Welcome to our dedicated page for Arrivent Biopharma news (Ticker: AVBP), a resource for investors and traders seeking the latest updates and insights on Arrivent Biopharma stock.
ArriVent BioPharma, Inc. (Nasdaq: AVBP) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of targeted therapies for EGFR-mutant non-small cell lung cancer (NSCLC) and solid tumors. Company announcements frequently highlight progress with its lead candidate firmonertinib, an oral, highly brain-penetrant, mutation-selective EGFR inhibitor, and updates on its emerging antibody-drug conjugate (ADC) pipeline.
Investors and observers following AVBP news can expect regular updates on pivotal and early-stage clinical trials. These include global Phase 3 studies such as FURVENT in first-line NSCLC patients with EGFR exon 20 insertion mutations and ALPACCA in first-line EGFR PACC mutant NSCLC, as well as Phase 1b data from the FURTHER trial in PACC mutant disease. News releases often provide detail on endpoints like progression-free survival, overall response rate, CNS responses, and safety findings reviewed by blinded independent central review.
ArriVent’s news also covers pipeline expansion beyond firmonertinib, particularly ARR-217 (MRG007), a CDH17-targeted ADC in gastrointestinal malignancies developed in collaboration with Lepu Biopharma. Updates may include regulatory milestones such as IND clearances, trial initiations, and preclinical data presentations. In addition, AVBP news items report on corporate developments, including public offerings of common stock and pre-funded warrants, board appointments, and the appointment of commercial leadership as the company prepares for potential future commercialization activities.
This AVBP news page aggregates these disclosures so readers can follow clinical milestones, regulatory designations, financing events, and strategic collaborations that shape ArriVent’s oncology-focused pipeline. For those tracking EGFR-mutant NSCLC and ADC developments, the feed provides a centralized view of the company’s reported progress over time.
ArriVent BioPharma (Nasdaq: AVBP) announced on Dec. 22, 2025 that the first patient was dosed in the global pivotal Phase 3 ALPACCA (FURMO-006) study evaluating once-daily oral firmonertinib 240 mg as first-line treatment for EGFR PACC mutant non-small cell lung cancer.
The randomized trial compares firmonertinib to investigator’s choice of osimertinib or afatinib, with primary endpoints of overall response rate (ORR) and progression-free survival (PFS) by blinded independent central review. Dose selection was based on prior data showing 16-month median PFS and a 68% confirmed ORR in the FURTHER trial. The study is designed to support potential accelerated and full regulatory approvals. Estimated annual incidence: ~42,000 global ex-China and ~6,200 US patients.
ArriVent BioPharma (Nasdaq: AVBP) reported Q3 2025 results and clinical progress on Nov 10, 2025. Key clinical milestones include final Phase 1b firmonertinib data in EGFR PACC mutant NSCLC showing meaningful PFS and CNS complete responses, FDA IND clearance for ARR-217 (CDH17-targeted ADC), and planned enrollment for the pivotal ALPACCA Phase 3 in Q4 2025. Topline pivotal data for firmonertinib in EGFR exon 20 insertion NSCLC is projected in early 2026. Financials: $305.4M cash and investments as of Sept 30, 2025, expected to fund operations into mid-2027.
ArriVent BioPharma (Nasdaq: AVBP) has appointed Brent S. Rice as Chief Commercial Officer (CCO). Rice brings over 25 years of experience in the biotechnology and pharmaceutical industry, most recently serving as SVP and global CCO at Autolus Therapeutics.
This strategic hire comes as ArriVent prepares for the potential approval and commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC). Rice's experience includes successfully transitioning Autolus from clinical-stage to commercial operations, leading Managed Markets at Juno Therapeutics, and spending 18 years at Amgen in various leadership roles.
ArriVent BioPharma (NASDAQ:AVBP) presented final proof-of-concept data from its global Phase 1b FURTHER trial for firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) at the 2025 World Conference on Lung Cancer. The study demonstrated significant efficacy with 16.0 months median progression-free survival and a 68.2% confirmed overall response rate at 240mg dosing.
Key highlights include 14.6 months median duration of response, confirmed CNS responses with complete responses, and rapid clearance of PACC circulating tumor DNA in 82% of frontline patients at 240mg. The drug showed broad activity across various PACC mutations and maintained a manageable safety profile consistent with EGFR-TKI class drugs. ArriVent plans to initiate the global Phase 3 ALPACCA study in the second half of 2025.
ArriVent BioPharma (NASDAQ:AVBP) reported Q2 2025 financial results and pipeline updates. The company highlighted positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, with plans to initiate the global Phase 3 ALPACCA study in 2H 2025. The company also dosed the first patient in a Phase 1 study of ARR-217, their CDH17-targeted ADC for gastrointestinal tumors.
Financially, ArriVent reported $254.5 million in cash and investments as of June 30, 2025, plus an additional $81.1 million raised in July 2025, extending their runway to mid-2027. The company's net loss increased to $95.8 million for H1 2025, compared to $39.3 million in H1 2024, primarily due to a $40 million upfront payment to Lepu Biopharma.
ArriVent BioPharma (Nasdaq: AVBP) has announced the pricing of a public offering expected to raise approximately $75 million in gross proceeds. The offering consists of 2,482,692 shares of common stock priced at $19.50 per share and pre-funded warrants to purchase up to 1,363,469 shares at $19.4999 per warrant.
The company has granted underwriters a 30-day option to purchase up to an additional 576,923 shares. The offering, led by Goldman Sachs, Citigroup, and Guggenheim Securities as joint book-running managers, is expected to close around July 3, 2025.
ArriVent plans to use the net proceeds to support activities for firmonertinib and other pipeline programs, along with working capital and general corporate purposes. The offering is being made pursuant to an automatic shelf registration statement filed with the SEC.
ArriVent BioPharma (Nasdaq: AVBP), a clinical-stage biopharmaceutical company, has announced plans for a $75 million public offering of common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered.
The offering will be managed by joint book-running managers Goldman Sachs & Co. LLC, Citigroup, and Guggenheim Securities. ArriVent plans to use the proceeds to support the development of firmonertinib and other pipeline programs, along with working capital and general corporate purposes.
The offering is being conducted through an automatic shelf registration statement on Form S-3ASR filed with the SEC on February 3, 2025. A preliminary prospectus supplement and accompanying base prospectus will be available on the SEC's website.
FAQ
What is the current stock price of Arrivent Biopharma (AVBP)?
What is the market cap of Arrivent Biopharma (AVBP)?
